Ligand-modified vesicular stomatitis virus glycoprotein displays a temperature-sensitive intracellular trafficking and virus assembly phenotype

Molecular Therapy

Volumn 9, Issue 1, 2004, Pages 76-84

  Guibinga, Ghiabe H ^a   Hall, Frederick L ^b   Gordon, Erlinda M ^b   Ruoslahti, Erkki ^c   Friedmann, Theodore ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Epeius Biotechnologies Corporation   (United States)

^c BURNHAM INSTITUTE   (United States)

Author keywords

Gene therapy; Lentivirus; Oncoretrovirus; Retargeting; Virus assembly; VSV G

Indexed keywords

AMINO ACID; COLLAGEN; LIGAND; PEPTIDE; VIRUS GLYCOPROTEIN; VIRUS VECTOR; VON WILLEBRAND FACTOR;

ANIMAL CELL; ARTICLE; BINDING ASSAY; BINDING SITE; CELL SURFACE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE THERAPY; GENETIC CODE; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; MICROSCOPY; NONHUMAN; PHENOTYPE; PROTEIN MODIFICATION; STATISTICAL SIGNIFICANCE; TEMPERATURE SENSITIVITY; TISSUE CULTURE; VESICULAR STOMATITIS VIRUS; VIRUS ASSEMBLY; VIRUS PARTICLE;

ANIMALIA; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; LENTIVIRUS; UNIDENTIFIED RETROVIRUS; VESICULAR STOMATITIS VIRUS;

EID: 1142287424     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ymthe.2003.09.018     Document Type: Article

References (37)

1. Yee, J.-K., Miyanohara, A., LaPorte, P., Bouic, K., Burns, J. C., and Friedmann, T. (1994). A general method for generation of high titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc. Natl. Acad. Sci. USA 91: 9564-9568.
2. Burns, J. C., Friedmann, T., Driever, W., Burrascano, M., and Yee, J.-K. (1993). Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells. Proc. Natl. Acad. Sci. USA 90: 8033-8037.
3. + cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. J. Virol. 70: 2581-2585.
4. Reiser, J., Harmison, G., Kluepfel-Stahl, S., Brady, R. O., Karlsson, S., and Schubert, M. (1996). Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proc. Natl. Acad. Sci. USA 93: 15266-15271.
5. Naldini, L., et al. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272: 263-267.
6. Vandendriessche, T., Naldini, L., Collen, D., and Chuah, M. K. (2002). Oncoretroviral and lentiviral vector-mediated gene therapy. Methods Enzymol. 346: 573-589.
7. Naldini, L., and Verma, I. M. (1999). Lentiviral vectors. In The Development of Human Gene Therapy (T. Friedmann, Ed.). Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
8. Hong, S. S., Magnusson, M. K., Henning, P., Lindholm, L., and Boulanger, P. A. (2003). Adenovirus stripping: a versatile method to generate adenovirus vectors with new cell target specificity. Mol. Ther. 7: 692-699.
9. Li, Y., Yao, X. M., Hong-Brown, L., and Massa, S. M. (2003). Adaptable modification of adenoviral tropism using a bifunctional ligand protein. Virus Res. 91: 223-230.
10. Volpers, C., et al. (2003). Antibody-mediated targeting of an adenovirus vector modified to contain a synthetic immunoglobulin G-binding domain in the capsid. J. Virol. 77: 2093-2104.
11. Nicklin, S. A., and Baker, A. H. (2002). Tropism-modified adenoviral and adeno-associated viral vectors for gene therapy. Curr. Gene Ther. 2: 273-293.
12. Belousova, N., Krendelchtchikova, V., Curiel, D. T., and Krasnykh, V. (2002). Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J. Virol. 76: 8621-8631.
13. Gordon, E. M., et al. (2000). Inhibition of metastatic tumor growth in nude mice by portal vein infusions of matrix-targeted retroviral vectors bearing a cytocidal cyclin G1 construct. Cancer Res. 60: 3343-3347.
14. Gordon, E. M., et al. (2001). Systemic administration of a matrix-targeted retroviral vector is efficacious for cancer gene therapy in mice. Hum. Gene Ther. 12: 193-204.
15. Martin, F., Chowdhury, S., Neil, S. J., Chester, K. A., Cosset, F. L., and Collins, M. K. (2003). Targeted retroviral infection of tumor cells by receptor cooperation. J. Virol. 77: 2753-2756.
16. Lavillette, D., Russell, S. J., and Cosset, F. L. (2001). Retargeting gene delivery using surface-engineered retroviral vector particles. Curr. Opin. Biotechnol. 12: 461-466.
17. Russell, S. J., and Cosset, F. L. (1999). Modifying the host range properties of retroviral vectors. J. Gene Med. 1: 300-311.
18. Guibinga, G. H., Miyanohara, A., Esko, J. D., and Friedmann, T. (2002). Cell surface heparan sulfate is a receptor for attachment of envelope protein-free retrovirus-like particles and VSV-G pseudotyped MLV-derived retrovirus vectors to target cells. Mol. Ther. 5: 538-546.
19. Kyte, J., and Doolittle, R. F. (1982). A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 157: 105-132.
20. Gordon, E. M., Zhu, N. L., Forney, P. M., Chen, Z. H., Anderson, W. F., and Hall, F. L. (2001). Lesion-targeted injectable vectors for vascular restenosis. Hum. Gene Ther. 12: 1277-1287.
21. Hall, F. L., et al. (1997). Targeting retroviral vectors to vascular lesions by genetic engineering of the MoMLV gp70 envelope protein. Hum. Gene Ther. 8: 2183-2192.
22. Klevanik, A. V. (2001). Hydrophobicity and prediction of the secondary structure of membrane proteins and peptides. Membr. Cell Biol. 14: 673-697.
23. Suarez, T., Gallaher, W. R., Agirre, A., Goni, F. M., and Nieva, J. L. (2000). Membrane interface-interacting sequences within the ectodomain of the human immunodeficiency virus type 1 envelope glycoprotein: putative role during viral fusion. J. Virol. 74: 8038-8047.
24. Schlegel, R., and Wade, M. (1985). Biologically active peptides of the vesicular stomatitis virus glycoprotein. J. Virol. 53: 319-323.
25. Abe, A., Chen, S. T., Miyanohara, A., and Friedmann, T. (1998). In vitro cell-free conversion of noninfectious Moloney retrovirus particles to an infectious form by the addition of the vesicular stomatitis virus surrogate envelope G protein. J. Virol. 72: 6356-6361.
26. Okimoto, T., Friedmann, T., and Miyanohara, A. (2001). VSV-G envelope glycoprotein forms complexes with plasmid DNA and MLV retrovirus-like particles in cell-free conditions and enhances DNA transfection. Mol. Ther. 4: 232-238.
27. Sharma, S., Miyanohara, A., and Friedmann, T. (2000). Separable mechanisms of attachment and cell uptake during retrovirus infection. J. Virol. 74: 10790-10795.
28. Li, E., Tabas, I., and Kornfeld, S. (1978). The synthesis of complex-type oligosaccharides. I. Structure of the lipid-linked oligosaccharide precursor of the complex-type oligosaccharides of the vesicular stomatitis virus G protein. J. Biol. Chem. 253: 7762-7770.
29. Robbins, P. W., Hubbard, S. C., Turco, S. J., and Wirth, D. F. (1977). Proposal for a common oligosaccharide intermediate in the synthesis of membrane glycoproteins. Cell 12: 893-900.
30. Hunt, L. A., Etchison, J. R., and Summers, D. F. (1978). Oligosaccharide chains are trimmed during synthesis of the envelope glycoprotein of vesicular stomatitis virus. Proc. Natl. Acad. Sci. USA 75: 754-758.
31. Gibson, R., Kornfeld, S., and Schlesinger, S. (11981). The effect of oligosaccharide chains of different sizes on the maturation and physical properties of the G protein of vesicular stomatitis virus. J. Biol. Chem. 256: 456-462.
32. Machamer, C. E., and Rose, J. K. (1988). Vesicular stomatitis virus G proteins with altered glycosylation sites display temperature-sensitive intracellular transport and are subject to aberrant intermolecular disulfide bonding. J. Biol. Chem. 263: 5955-5960.
33. de Silva, A., Braakman, I., and Helenius, A. (11993). Posttranslational folding of vesicular stomatitis virus G protein in the ER: involvement of noncovalent and covalent complexes. J. Cell Biol. 120: 647-655.
34. Balch, W. E., McCaffery, J. M., Plutner, H., and Farquhar, M. G. (1994). Vesicular stomatitis virus glycoprotein is sorted and concentrated during export from the endoplasmic reticulum. Cell 76: 841-852.
35. Sharma, S., Murai, F., Miyanohara, A., and Friedmann, T. (1997). Noninfectious virus-like particles produced by Moloney murine leukemia virus-based retrovirus packaging cells deficient in viral envelope become infectious in the presence of lipofection reagents. Proc. Natl. Acad. Sci. USA 94: 10803-10808.
36. Maniatis, T., Fritsch, E. F., and Sambrook, J. (1982). Molecular Cloning: A Laboratory Manual, 1st edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
37. Agard, D. A., Hiraoka, Y., Shaw, P. J., and Sedat, J. W. (1989). Fluorescence microscopy in three dimensions. Methods Cell Biol. 30: 353-377.